CELLS for CELLS treats the first-ever patient with an exosome-produced therapy for osteoarthritis
18 juil. 2022 15h54 HE
|
Cells for Cells
SAN FRANCISCO, July 18, 2022 (GLOBE NEWSWIRE) -- Cells for Cells ("C4C"), a clinical-stage biotech pioneering allogeneic stem cell and stem-cells-derived therapeutics for high-impact chronic...
Global Exosomes Market Surpass USD 2,200 Million by 2030 - Exclusive Report By Acumen Research And Consulting
13 juin 2022 14h06 HE
|
Acumen Research and Consulting
SEATTLE, June 13, 2022 (GLOBE NEWSWIRE) -- The global exosomes market size is estimated to grow a CAGR above 34% over the forecast timeframe and reach a market value of around USD 2,273 million by...
Aesthetic Management Partners Announces Exclusive Distribution Agreement With Estar Medical
23 mai 2022 08h00 HE
|
Aesthetic Management Partners
CORDOVA, Tenn., May 23, 2022 (GLOBE NEWSWIRE) -- Estar Medical, the maker of Eclipse PRP® and Tropocells®, has signed an exclusive long-term marketing and distribution agreement with Aesthetic...
Codiak BioSciences Reports First Quarter 2022 Financial Results and Operational Progress
05 mai 2022 16h01 HE
|
Codiak BioSciences, Inc.
– Codiak to provide data from ongoing exoSTING™ and exoIL-12™ clinical trials in late 1H 2022 – – Anticipate first patients dosed in exoASO™-STAT6 Phase 1 clinical trial in 1H 2022 – – Data from...
Codiak Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer
02 mai 2022 09h00 HE
|
Codiak BioSciences, Inc.
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a...
Codiak Presents New Preclinical Data Supporting Development of a Broadly Protective Pan Beta-Coronavirus Vaccine
20 avr. 2022 16h40 HE
|
Codiak BioSciences, Inc.
– Engineered exosome vaccine construct generated durable, comprehensive immunity in vivo – CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a...
Codiak’s exoASO™-C/EBPβ Demonstrates Significant Systemic Anti-Tumor Activity via Targeting Immune-Suppressive Myeloid Cells
08 avr. 2022 13h00 HE
|
Codiak BioSciences, Inc.
– New preclinical data presented at AACR Annual Meeting 2022 – – Intravenous exosome candidate engineered for tropism precisely targets transcription factors in myeloid cell subpopulations – –...
Codiak BioSciences Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Progress
10 mars 2022 16h01 HE
|
Codiak BioSciences, Inc.
– Reported positive initial data from exoSTING™ clinical trial; on track to provide data from all dose escalation cohorts in late 1H 2022 – – Investigational New Drug (IND) application cleared for...
Data from Codiak’s exoASO™-STAT6 Preclinical Development Program for the Treatment of Primary and Metastatic Hepatic Cancers Published in Science Advances
18 févr. 2022 14h00 HE
|
Codiak BioSciences, Inc.
– Unprecedented monotherapy activity via macrophage reprogramming in preclinical models – – Phase 1 study expected to begin in 1H 2022 – CAMBRIDGE, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Codiak...
Codiak BioSciences to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference
06 janv. 2022 09h00 HE
|
Codiak BioSciences, Inc.
CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a...